PRCT: HYDROS conversion and replacements underpin growth, with positive adjusted EBITDA expected in Q4

What happened

PROCEPT BioRobotics reported Q3 revenue growth of 18% year over year and a 22% rise in U.S. procedures, attributing growth in part to HYDROS adoption and replacement procedures. It kept FY26 revenue guidance unchanged and expects positive adjusted EBITDA, a measure of operating performance excluding certain items, in Q4.

Confirmed

Global impact / market context

More procedures and continued HYDROS adoption can support sales, while replacement procedures may add demand beyond new installations. Expected positive adjusted EBITDA in Q4 would indicate improved operating performance, but unchanged FY26 revenue guidance means the company has not raised its full-year sales outlook.

Analyst inference

The outlook combines strong recent growth with a steady full-year revenue forecast and a stated ~20% growth baseline for 2027. Investors may weigh whether procedure volumes and HYDROS adoption can sustain growth, while treating expected Q4 profitability as a forecast rather than a reported result.

Analyst inference

What to watch

1. Check whether Q4 results show positive adjusted EBITDA as management expects; this would indicate that the company reached its stated near-term operating-performance goal. Analyst inference
2. Track subsequent U.S. procedure growth and HYDROS adoption, since the article identifies both as contributors to Q3 growth and potential support for future revenue. Analyst inference
3. Compare reported FY26 revenue with the unchanged guidance, and assess whether management continues to describe roughly 20% growth as the 2027 baseline. Analyst inference

Evidence

• Original source link unavailable